Dr. Mack Roach, III and Dr. Martin Spahn presented a debate on “Oligometastases: RP Is Experimental and Should Only Be Done in the Context of a Prospective Clinical Trial” versus “RP and SBRT to Bone Disease Is a Reasonable Management Strategy for Men with Oligomets” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.

 

 

 

Keywords: prostate cancer, oligometastatic disease, radical prostatectomy, stereotactic body radiation therapy

How to cite: Roach, Mack III and Spahn, Martin. “Debate: How Should We Manage Oligometastatic Disease?” Grand Rounds in Urology. October 14-16, 2016. Accessed Mar 2024. https://dev.grandroundsinurology.com/debate-how-should-we-manage-oligometastatic-disease

This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.